Autolus Q2 AUCATZYL sales hit $45.7 million; 2026 revenue guidance raised
Autolus reported second-quarter 2026 AUCATZYL net product revenue of $45.7 million, up from $20.9 million a year earlier, and raised its full-year 2026 AUCATZYL revenue guidance to $140 million to $150 million from $120 million to $135 million. Net loss narrowed to $39.1 million from $47.9 million, and the company said its cash runway now extends into Q2 2028 after a credit facility draw.
Key points
- Q2 2026 net product revenue was $45.7 million, versus $20.9 million in Q2 2025 and $26.2 million in Q1 2026.
- Gross margin was 55% in Q2 2026, up from 6% in Q1 2026 and negative in all 2025 quarters.
- Net loss was $39.1 million, or $(0.15) per share, compared with $47.9 million, or $(0.18) per share, a year earlier.
- Cash, cash equivalents and marketable securities were $201.6 million at June 30, 2026, versus $229.4 million at March 31, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.